Skip to main content

Table 1 Patient characteristics

From: Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer

 

All (n = 124)

PCI (n = 29)

non-PCI (n = 95)

P

Age, year (range)

72 (37–88)

65 (37–74)

74 (37–88)

<0.0001

Male

113 (91)

27 (93)

86 (90)

0.778

Smoking status

   

0.721

 Current

61 (49)

15 (52)

46 (48)

 

 Former

60 (48)

14 (48)

46 (48)

 

 Never

2 (2)

0

2 (2)

 

 Unknown

1 (1)

0

1 (1)

 

Number of packets

46 (0–210)

60 (12–140)

45 (0–210)

0.226

Clinical stage

   

0.0009

 Stage I/II

51 (41)

5 (17)

46 (49)

 

 Stage III

73 (59)

24 (83)

49 (52)

 

ECOG PS

   

0.337

 0

70 (56)

20 (69)

50 (53)

 

 1

50 (40)

8 (28)

42 (44)

 

 2

4 (3)

1 (3)

3 (3)

 

Initial treatment

   

0.094

Chemoradiotherapy

61 (49)

19 (66)

42 (44)

 

 Radiotherapy

4 (3)

0 (0)

4 (4)

 

 Surgery

41 (34)

8 (28)

33 (35)

 

 Chemotherapy

18 (15)

2 (7)

16 (17)

 

Response to initial treatment

   

0.0052

 Complete response

82 (66)

25 (86)

57 (60)

 

 Good partial response

42 (34)

4 (14)

38 (40)

 

Cranial MRI before PCI

85 (69)

28 (97)

57 (60)

<0.0001

Observation period (month)

20 (6–94)

20 (6–82)

20 (6–94)

0.945

  1. Data are numbers of patients (percentage of patients) otherwise indicated
  2. PCI prophylactic cranial irradiation; ECOG PS Eastern Cooperative Oncology Group performance status